The phase of easing restrictions and the “re-opening” in various states and countries will require frequent testing and re-testing of as many individuals as possible (health care workers in particular) for the foreseeable future to sustain viral containment. Addressing this persistent problem will use new technologies beyond those that are currently available. The new technologies should be inexpensive and readily accessible. Most importantly, the systems should provide rapid and dependable readouts to prompt immediate identification and isolation of those carrying Sudden Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Thus, there is a need for development of an easy-to-use non-laboratory handheld test device capable of testing samples in real time without involving trained technician.
Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the present disclosure. Moreover, in the drawings, like reference numerals designate corresponding parts throughout the several views.
Disclosed herein are various embodiments related to handheld sensors for rapid and sensitive detection and quantification of conditions from saliva. Currently, the most commonly used method for detecting potential diseases is to test body fluids, such as serum urine, and blood, using biochemical analysis. However, when the biomarker is in a high-concentration ionic solution, the measurement results may be severely affected by shielding effects, or so-called screening effects. Reference will now be made in detail to the description of the embodiments as illustrated in the drawings, wherein like reference numbers indicate like parts throughout the several views.
Biosensor technologies have progressed to achieve high sensitivity and extended dynamic range over a wide concentration range of biomarkers. Semiconductor-based sensors, such as the ion-sensitive field-effect transistor (ISFET), biologically functionalized field-effect transistor (BioFET), and DNA field-effect transistor (DNAFET), can provide reliable and fast measurements for composition analysis by functionalizing the transistor's gate electrode with antibodies to detect antigens in a solution. However, in a highly ionic concentration solution such as saliva, the Debye length is shortened.
To overcome the above challenges, two techniques have been developed. First, a double-layer structure utilizes charge induction to reduce the screening effect. The double-layer sensor architecture features a gate electrode separated from the solution to give a stable voltage to the gate of the transistor, performing voltage to current conversion and utilizing charge induction to reduce the screening effect. It also allows the sensing area to be physically separated from a handheld device housing the sensing and readout circuits. An electrical double layer (EDL) gated FET biosensor that is capable of direct detection of target analytes in solutions has been developed. The disposable sensor chip can include a substrate, sensing lines, passivation layer and cap layer. The electrode can be functionalized for sensing, and a window or opening can allow visualization of a sample applied to the functionalized electrode. U.S. non-provisional application entitled “Modularized Inexpensive Detection of Cerebral Spinal Fluid for Medical Applications” having serial no. 16/851,859, filed Apr. 17, 2020, which is hereby incorporated by reference in its entirety, provides additional information about the biosensor.
The second technique, called a synchronized double-pulsed method, ensures that the sensor transistor and circuits are reset before each measurement so that accurate test results can be obtained with high sensitivity in each test. In a conventional test method with a constant bias voltage on the transistor's drain, the charges will accumulate on the drain and affect sensor accuracy. Instead of applying a constant bias voltage, synchronized double short pulses are applied to both drain and gate electrodes of sensor transistor to ensure that the sensor electrode is reset before each measurement without accumulating charges from previous measurements.
In a single-pulse readout circuit, charges may accumulate on the gate and drain after each measurement because of the floating-gate effect.
In electrolytes, Debye length describes the distance at which a charge can act on another charge effectively. Assuming the electrolyte is monovalent and symmetrical, the Debye length can be derived as
where λD is Debye length, ϵr is the dielectric constant, ϵ0 is vacuum permittivity, R is the gas constant, F is the Faraday constant, T is absolute temperature, and C0 is electrolyte concentration in molarity (M). The Debye length can be also calculated from conductivity, σ
where ϵ is the dielectric permittivity and D is the diffusion coefficient. When the pulse is applied to the electrode, the double-layer forms at the solution-electrode interface and creates a double-layer capacitance, which is correlated with the electrolyte concentration. In an isolated system where the net plate charge is fixed, the lateral redistribution of the surface charge density coupled to the transverse reorganization of the ionic charge distribution in the electrolyte can cause the EDL capacitance to vary.
A relaxing gap capacitor can be used to model the effects of the varying capacitance.
where A is the plate area, l0 is the initial distance between two plates, and k is the spring constant. By Hooke's Law, spring length is determined by:
Assuming that the whole system is in the damped simple harmonic motion, lcan be derived as:
where ω is the angular frequency, and φ is the phase.
According to the above equations, in a fixed analyte concentration, the damping time to steady-state corresponds to the capacitance and conductivity of the solution. The relative dielectric constant (ϵr) of the solution decreases as the ionic concentration increases. Besides, the Debye length is inversely correlated with the ionic concentration, resulting in an increase in the EDL capacitance as the conductivity increases. Therefore, the capacitance can be denoted as:
where Vpulse2 is the amplitude of the gate pulse pattern sent to the test strip.
On a macroscopic scale, when the electrostatic energy becomes stable in the capacitor, the final DC value of the gate voltage can be determined by the ratio of the EDL capacitance and parasitic capacitance, CGS and CGD. Therefore, for different concentrations of analytes, the gate voltage varies because of the capacitive voltage divider. Theoretically, the analytes can be assessed by measuring the voltage waveform pattern at the gate terminal; however, to avoid other charge leakages affecting measuring results, the drain current, which is amplified by the current mirror gain, is used to assess the analytes in the proposed system.
As observed from the waveform of the sensing electrodes, the analyte information can be in the form of the settling response and the stable voltage of the gate terminal. Measuring the voltage in a stable state can give precise results, and the data recorded from the settling response can provide substantial gain and kinetic dynamics for the charge reaction between the solution and electrode.
The disclosed technology may be used to provide non-laboratory testing with a degree of precision that can avoid complications resulting from current tests being performed only at limited sites due to cost and expertise. The sensing electrode can be fabricated on a disposable strip and can be utilized with a handheld device for data processing and storage. This non-laboratory device can detect a wide range of biomarkers by inserting the specific disposable testing strip into the associated handheld device or an extension cable connecting to the handheld device. An optional detachable connection such as a cable (e.g., USB cable) can be used between the disposable test strip and the portable (or handheld) sensing and readout device; serving as an extension to further separate the test strip and the sensing and readout device, for better sanitization process or other purposes. The ability to function in highly ionic solutions is important if whole blood, urine, nasal secretions, saliva, etc. are to be analyzed at the non-laboratory testing location. U.S. non-provisional application entitled “Low Cost Disposable Medical Sensor Fabricated on Glass, Paper or Plastics” having Ser. No. 16/206,493, filed Nov. 30, 2018, demonstrates the use of this concept to measure the low volume (10 to 50 μl) of Zika virus and U.S. non-provisional application entitled “Modularized Inexpensive Detection of Cerebral Spinal Fluid for Medical Applications” having Ser. No. 16/851,859, filed Apr. 17, 2020, demonstrates its use for the detection of cerebral spinal fluid (CSF), both of which are hereby incorporated by reference in their entireties, but the sensors and methods can be extended to include detection and quantification of SARS-CoV-2, troponin I protein (heart attack detection), or other biomarkers such as, e.g., MRSA or HIV in high ionic solutions.
This synchronized double-pulsed method in combination with the double-layer structure allows the test strip sensing area to be externalized from the sensor electronics in the handheld device, and an optional extension cable similar to USB cable can be used to further separate test strip from the handheld device (test strip inserted into one end of extension cable whereas the other end of extension cable is inserted into the handheld device).
Target detection is based upon the selective recognition and interaction of two protein molecules (akin to a receptor protein binding to its cognate ligand), such that either the receptor or ligand is immobilized on the test strip electrode and serves as the “detection” protein, while the second protein, suspended in a biological fluid (e.g. blood, urine, saliva etc.), serves as the “target.” When a test solution containing the target is applied to the test strip, the selective recognition and binding (complex formation) between the target and immobilized detection protein, changes the charge distribution on the test electrode in response to an electrical pulse, which is then amplified to the output of the transistor.
This principle was demonstrated with the use of a receptor (anti-SARS-CoV-2 spike antibody) as the “detection” protein and its ligand (SARS-CoV-2 spike protein) as the “target.” In this configuration (#1) the test system is used to detect the presence of SARS-CoV-2 spike antigen (and by extension the SARS-CoV-2 virus) in the saliva of test subjects. The converse configuration (#2) is also possible, whereby the ligand of the pair (e.g. the SARS-CoV-2 spike protein) is immobilized on the electrode and is used to “detect” the presence of a receptor protein (e.g. anti-SARS-CoV-2 spike antibody) in a biological fluid. In configuration #2, the system is used to detect the presence of anti-SARS-CoV-2 antibody in the blood, or serum, of test subjects, indicative of a humoral immune response from prior SARS-CoV-2 infection.
As the gate pulse passes through the test strip sensing area and analyte, Vsen varies according to the double-layer capacitance on the electrode-solution interface until the energy stored in the double-layer capacitor remains stable. The corresponding voltage at the gate terminal of the NMOS transistor creates the drain current, Isen, which is detected by the following I-to-F converter. The change in Isen results in a change in the output frequency of the oscillator. Then, a delay-line based TDC converts the I-to-F outputs into digital codes that represent the analyte concentration.
Pulse Pattern Generator.
The gate and drain pulses and the pulse delay between them can be reconfigured for different sensors or different concentrations. For example, when measuring low-concentration troponin I, the response is often long, so an extended pulse signal can be used to provide sufficient time to acquire steady state information. For measuring other analytes with a faster response, the pulse pattern generator can create short pulses to increase the sampling rate. In the design, the drain pulse pattern can be adjusted from 10Tclk to (n−1)Tclk, and the gate pulse pattern can be adjusted from 8Tclk to (n−3)Tclk, where n is the number of delay cells.
In order to detect various substances, which may have different reaction potentials, the sensing and readout circuits can be configured to generate an accurate voltage to stimulate the chemical reaction. In the pulse pattern generator, a VDD-adjustable buffer can be implemented to adjust the amplitude of the gate pulse pattern. A schematic diagram of the VDD adjustment circuit (generator and buffer) is shown in
Current to Frequency Converter (I-to-F).
To sense the drain current generated by Vsen, a current mirror is implemented. Therefore, IBIAS can be written as:
I
BIAS
=αl
SEN=αβ(VSEN−Vth,n)2 (7)
where α is the size ratio between M1 and MBIAS in
with the relation between ISEN and Ioutput, the concentration of the analyte can be obtained.
Delay-line-based Time-to-digital Converter (TDC). In the TDC design, the limit of detection for the counter-based TDC can be determined by the clock speed, leading to tradeoffs among power, area, and resolution. The delay-line-based TDC has the advantage of first-order noise shaping, and the minimum delay time of each block determines the resolution, which benefits from the advanced technology node. Thus, the delay-line TDC can achieve a better resolution, smaller area, and lower power consumption than the counter-based TDC.
Referring to
The handheld device includes power management units, a reconfigurable pattern generator, a current-to-frequency converter, and digital signal processing units. One of the electrodes of the sensor strip can be connected on the gate of the FET. The voltage variation from the interaction of a detection antibody and target analyte (e.g. host protein, viral antigen, disease biomarker etc.) on the electrodes of the sensor strip modulates the current at the drain of the FET. This detected signal can then be converted to the frequency of an oscillator, whose oscillation frequency depends only on the sensor current and a fixed resistor value. The design is insensitive to the amplitude noise from the devices and voltage supply and therefore can achieve low electrical noise and excellent stability. The frequency signal can be digitized using a frequency counter (e.g., 12-bit). The frequency counter provides first-order noise shaping intrinsically. The design uses digital architecture, thus providing the advantages of high design flexibility, compact size, and low power consumption. The pattern generator stimulates the biosensor with a reconfigurable pulse duration (100-1200 μs), delay time (5-40 μs) between the gate and drain stimuli, counting duration (10-100 μs), and gate amplitude (1.2-1.52V) to optimize the sensor.
A wireless communication module (e.g., Bluetooth®) can be included in the handheld device, for wireless data transmission to a user device such as, e.g., a smartphone, or a computer. Together with an application executed on the smartphone, computer, or other remote or mobile device, the Bluetooth® wireless link can make the handheld device easy to use and compatible with many existing personal devices and equipment.
Referring to
Wth advanced silicon semiconductor foundry technologies, instead of using off-shelf components on a circuit board, sophisticated biosensor readout circuits can be integrated into a single chip to reduce the size of the handheld devices and significantly improve signal-to-noise ratio by eliminating the wire coupling noise and signal losses. The dimensions of an integrated circuit chip can be much smaller (e.g., 0.66 m×1.37 mm) than the size of a circuit board using off-shelf components. The wire coupling noise and signal loss usually limit the sensitivity of the biosensor readout frontends, especially for very weak bio-signal measurements. Without the additional wiring, the device sensitivity and reliability will also be significantly improved.
In some embodiments, the chip can be fabricated in a 0.18 μm standard CMOS process. To decrease the interference from the environment, the chip can be insulated with epoxy after wire bonding. A chip comprising the pattern generator, I-to-F converter, TDC and 8-bit counter was fabricated in a 0.18 μm standard CMOS process with an area of 0.92 mm2. The sensing and readout integrated circuit chip were assembled on a circuit board for functional characterization. The two-electrode sensor can be fabricated using, e.g., an Au surface and modified with antibodies for, e.g., troponin I measurement, SARS-CoV-2 antigen measurement, etc.
The test strips can be made of multiple patterned conductive layers on plastics as the electrodes with either printed silver layer covered with a carbon layer, or gold-based electrodes deposited by, e.g., electric-plating or metal sputter deposition.
Although the detection time can be less than 3 sec, the testing can be performed with a delay of, e.g., 30 sec or greater in some applications after applying the sample to the test strip in order to ensure the binding of virus to the antibody. This prototype was designed and demonstrated as an easy-to-use handheld device for individuals at home, health care professionals in their offices and clinics, shops, restaurants, airlines, theaters, sports venues etc. to perform real-time testing and displaying the results. Similar to that shown in
The sensor can be functionalized to detect a wide range of targets, depending on conditions. For example, there are antibodies available for targeting the spike, envelope, and nucleocapsid proteins of the SARS-CoV-2 virus. There are antibodies available that target different regions of the spike protein, e.g., one that targets the 17 amino acid sequence near the center of the spike protein, within amino acid 550-600 and another that targets a 20 amino acid sequence near the carboxy terminus, both are available from ProSci Inc.
The sensor can also be functionalized for measurement of cardiac troponin I. First, the two electrodes are coated with gold nanoparticles (Vida-Bio, GN3) before post-modification. For surface modification, gold electrodes can be treated with ethanol to remove organic contaminants. The self-assembled monolayers can be formed by immersing the gold electrodes in an ethanolic 10 mM solution of 12-mercaptododecanoic acid (MDA, C12H24O2S, Sigma-Aldrich) in a sealable container for 18 hours. After that, the MDA-modified gold electrodes can be carefully rinsed and cleaned with ethanol and blown dry with a stream of nitrogen gas. The MDA-modified gold electrodes can then be immersed in an aqueous solution of 10 mg/ml 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Sigma) and 2.5 mg/ml N-hydroxysuccinimide (NHS, Fluka) in citrate buffer solution (pH 5.0) for 1 hour [19]. Then, the MDA-modified gold electrodes can be coated with 100 μg/ml cardiac troponin I antibody (TnI, GeneTex) for 1 hour to immobilize the TnI on the activated MDA-SAM gold electrodes with chemical bonding.
Due to different test subjects or body conditions of the same test subject at different time points, the background sensor output signal may be different. To resolve this issue, a differential sensor can be used which comprises two sets of electrodes and micro-fluidic channels fabricated on the same strip.
As illustrated in
The software application can be developed for user devices such as, e.g., smartphones, tablets, computers or other computing devices. The application can interact with an MCU on the handheld sensor device through a wireless link, e.g., a Bluetooth®, to collect test data, perform simple analysis, and display the test outcomes (positive or negative). The application can also send the detailed test data, with user's consent, to healthcare professionals for further analysis. Wth user's consent, the test data (without user's personal identifiable information) can be collected by a database on, e.g., a secured server. With potentially a large number of users, the large amount of collected data can be valuable for real-time data analytics by researchers to understand the disease epidemiology and help accelerate reopening and economic recovery. The application can be configured so as not to transmit user's personal identifiable information, but only basic demographic and geographic (zip code) information to be associated with the test data.
Microfluidics-based component separation can be employed to avoid sample clogging and compromise of separation efficiency, especially for the application of small sample volumes.
Saliva has been shown to harbor SARS-CoV-2 virus at loads comparable to, if not greater than nasopharyngeal secretions, offering a clinical matrix with convenient access amenable to self-collection. To address the current testing shortfall, a novel field effect transistor (FET)-based platform was developed with the ability to detect SARS-CoV-2 spike protein in saliva with exquisite sensitivity, in less than 30 seconds. As disclosed, the handheld system employs disposable sample test strips, offering true point-of-care, non-laboratory sensor technology.
Human saliva has been shown to harbor SARS-CoV-2 throughout the course of infection in levels proportional to systemic viral load and offers painless, convenient access from the oral cavity. The convenience of saliva has been exploited to document disease progression among individuals infected with Zika virus and Ebola during their respective outbreaks. In this regard, SARS-CoV-2 content in saliva can be a more reliable index of viral load among individuals than secretions from nasopharyngeal swabs. The use of saliva as a biological test medium has distinct technical advantages: (1) collection is simple, fast, painless, and non-invasive. Nasopharyngeal swab, in contrast, requires insertion of a long cotton swab deep within the nasal passages, which is manually rotated to collect secretions from the sensitive mucosa. The procedure is not only unpleasant for the test subject but must be administered by trained technicians. (2) Moreover, unlike the nasopharyngeal swab test, the collection of saliva does not induce a sneeze or cough response and thus poses a reduced risk for health care workers, test administers or assistants.
Viral load in saliva has been found to be highest 1-3 days prior to symptom onset and gradually decline thereafter, possibly explaining rapid spread of the virus. Serum antibody against the SARS-CoV-2 spike protein has been detected earlier and more frequently than antibodies against the nucleocapsid. The presence of the virus was examined in 25 patients while correlating the results with comorbidities and levels of lactase dehydrogenase (LDH) and ultrasensitive reactive C protein (usRCP). The drooling technique was utilized to collect saliva, thereby isolating the salivary fluid from sputum or bronchial fluids. It was found that the virus was present in saliva in 100% of the Coronavirus Infectious Disease 2019 (COVID-19) patients confirmed by positive nasopharyngeal RT-qPCR (reverse transcription quantitative polymerase chain reaction).
Recombinant peptide corresponding to amino acid sequences found near the n-terminal region of the S2 subunit of the SARS-CoV-2 spike protein, was purchased from ProSci and suspended in PBS at 200 μg/mL. The peptide solution was then serially diluted in artificial saliva (Pickering Laboratories) to obtain the desired concentrations (down to 1 fg/mL). Testing of the sensor platform provided repeatable detection down to the order of 0.7 fM, 1 fg/mL.
It was investigated if the strip functionalized with Anti-SARS-CoV-2 antibody could detect SARS-CoV-2 spike antigen when presented on the surface of the virus in the context of human saliva. Heat-inactivated SARS-CoV-2 was employed and diluted in human saliva pooled from multiple donors.
The sensor functionalized for detection of troponin I was tested with the devised readout IC.
By taking ISFET as the reference, a sensor readout circuit with a double-pulse mechanism was developed that is suitable for a variety of sensors. Furthermore, a readout method was implemented using digital circuits, which not only increases the noise tolerance but also prevents analyses from being affected by non-ideal effects on the amplifier. The sensing time for the disclosed sensing system is significantly lower than other cardiac troponin I measurement methods, and there is a reduction in the charge accumulation effects. Wth the high SNR, the detection limit can be as low as 59.76 pg/mL.
This disclosure presents a double-pulsed readout circuit for monitoring SARS-CoV-2, cardiac troponin I, and other biosensing applications. The double-pulse method can reduce the charge accumulation on the channel of the sensing transistor. The signals can be generated from a reconfigurable pattern generator. With the timing interval between two pulses, the sensing path can be reset, reducing charge accumulation on the drain current path and the sensor. When the pulse is applied to the electrode, different concentrations of the analyte induce changes in the gate voltage and the drain current of the transistor. The current information can then be converted by, e.g., an I-to-F converter and a delay-line-based TDC. The measurements show an R2 linearity of 0.98 and a sensitivity of 1.77 Hz/pg-mL with 72.43 dB SNR while only consuming 124 μW at a 1.2-V supply. The readout circuitry provides a reconfigurable pulse width, amplitude, and recording window length for a wide range of biosensing applications. The design improves the measurement linearity, sensitivity, and SNR using the time-domain readout technique.
It should be emphasized that the above-described embodiments of the present disclosure are merely possible examples of implementations set forth for a clear understanding of the principles of the disclosure. Many variations and modifications may be made to the above-described embodiment(s) without departing substantially from the spirit and principles of the disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure and protected by the following claims.
It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of “about 0.1% to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1% to about 5%, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. The term “about” can include traditional rounding according to significant figures of numerical values. In addition, the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
This application is a continuation-in-part of co-pending U.S. non-provisional application entitled “Modularized Inexpensive Detection of Cerebral Spinal Fluid for Medical Applications” having Ser. No. 16/851,859, filed Apr. 17, 2020, which claims priority to, and the benefit of, U.S. provisional application having Ser. No. 62/835,962, filed Apr. 18, 2019, both of which are hereby incorporated by reference in their entireties.
Number | Date | Country | |
---|---|---|---|
62835962 | Apr 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16851859 | Apr 2020 | US |
Child | 17025664 | US |